- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") announces the publication of correspondence in the June 23, 2007 issue of The Lancet that demonstrates new evidence that further defines the infectious role of Calcifying Nanoparticles (CNPs).
The case report involves accidental human eye exposure to CNPs and a strong immune response against proteins carried by the nanoparticles. The antibody persisted over 10 years at a high level. The condition was diagnosed by the Company's ELISA blood test.
"These findings support our underlying goal on developing diagnostics and therapies that target the infectious agent that ultimately leads to pathological calcification," commented Dr. Benedict Maniscalco, Nanobac's Medical director.
About Nanobac Pharmaceuticals Inc.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information and to read the entire article, visit our website at: http://www.nanobac.com .
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
For more information, please click here
Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
Jens Dalsgaard, 415-884-0348
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
The NanoWizardŽ AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Ultrasensitive sensor using N-doped graphene July 26th, 2016